SFG
BCRX icon

Steward Financial Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

Steward Financial Group’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$0 Buy
+8
New +$57 ﹤0.01% 1335
2023
Q2 		– Sell
-57
Closed – – 503
2023
Q1 		$0 Buy
57
+17
+43% +$164 ﹤0.01% 727
2022
Q4 		$0 Buy
+40
New +$499 ﹤0.01% 561
2022
Q3 		– Sell
-40
Closed – – 197
2022
Q2 		$0 Buy
+40
New +$413 ﹤0.01% 985

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

Steward Financial Group's BCRX Position: Q3 2023 in Review

Steward Financial Group opened a new position in BioCryst Pharmaceuticals (BCRX) in Q3 2023: 8 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #1335 among its holdings. This is a return to the name: Steward Financial Group previously reported a position in BCRX as recently as Q1 2023.

Steward Financial Group first reported a position in BCRX in Q2 2022 and has held it in 4 quarters since. 233 funds tracked by Wall St. Rank hold BCRX as of Q3 2023.

  • Steward Financial Group held 8 shares of BioCryst Pharmaceuticals worth $0 as of Q3 2023.
  • BioCryst Pharmaceuticals was a new Steward Financial Group position in Q3 2023.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Steward Financial Group's portfolio in Q3 2023, its #1335 holding.
  • Steward Financial Group first reported a position in BioCryst Pharmaceuticals in Q2 2022 and has held it in 4 quarters since.
  • 233 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2023.

Based on Steward Financial Group's 13F filing for Q3 2023, filed 23 Oct 2023.